447 filings
Page 2 of 23
EFFECT
9ybiapmy
24 Oct 23
Notice of effectiveness
12:15am
EFFECT
anlxk
24 Oct 23
Notice of effectiveness
12:15am
UPLOAD
8x0 awcv4ih6365
24 Oct 23
Letter from SEC
12:00am
POS AM
mdi1p8s8anfe8oxf63
20 Oct 23
Prospectus update (post-effective amendment)
4:29pm
POS AM
rh3jexe
20 Oct 23
Prospectus update (post-effective amendment)
4:28pm
F-3
l3yielxof
20 Oct 23
Shelf registration (foreign)
4:23pm
D
hoqcc30xk
19 Oct 23
$1.97 mm in equity / options / securities to be acquired, sold $1.97 mm, 11 investors
4:17pm
S-8
pso hl7e43
12 Oct 23
Registration of securities for employees
4:43pm
6-K
gp821xo6qmziw
29 Sep 23
Current report (foreign)
8:01am
6-K
3pecjf429
21 Sep 23
Akari Therapeutics Announces Existing Investors Support the Company
8:00am
6-K
pmzahxph5w5m 7v
5 Sep 23
Current report (foreign)
9:00am
6-K
1kwke v2h62
18 Aug 23
from 6-K
8:00am
F-6 POS
bk2tg
17 Aug 23
Automatic registration for ADRs (post-effective amendment, foreign)
4:27pm
6-K
atbzkbmps9myq3r8f
15 Aug 23
Akari Therapeutics, Plc Announces ADS Ratio Change
8:00am
6-K
l5erf6 00kgxa9rj
2 Aug 23
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
8:00am
6-K
ozq 310vyzyxh08sq
27 Jul 23
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation
8:00am
6-K
vfncs2jr5vu0an4s0
25 Jul 23
Current report (foreign)
8:30am
6-K
yywpcqgasrp1d3of2
19 Jul 23
Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
8:00am
6-K
jjoz 2nyg
13 Jul 23
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
8:30am
6-K
is7cb63ms0 yy8g
11 Jul 23
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
8:30am